Key result
Carriers of at least one T allele in the VKORC1 C1173T polymorphism had a increased risk of severe bleeding when using phenprocoumon compared to CC genotype individuals.
Why the study?
Does the VKORC1 C1173T polymorphism increase bleeding risk in patients on vitamin K antagonist therapy?
Case-Control (n=330)
Yes
Does the VKORC1 C1173T polymorphism increase bleeding risk in patients on vitamin K antagonist therapy?
The VKORC1 C1173T polymorphism is associated with an increased risk of severe bleeding in patients treated with phenprocoumon, highlighting a potential role for genetic testing to guide vitamin K antagonist therapy.
Answers are grounded in this paper and cite their sources.
Does not support routine VKORC1 testing for phenprocoumon; leaves open whether genotyping improves VKA safety in prospective trials.
BACKGROUND: A C1173T polymorphism in intron 1 of the VKORC1 gene has been claimed to determine the interindividual variability in the response to vitamin K antagonist therapy (VKA), but it is unknown whether it also influences bleeding risk. We aimed to confirm the relationship between C1173T status and phenprocoumon or acenocoumarol use, and to examine the risk of severe bleeding for the various genotypes. METHODS AND FINDINGS: We studied this in a case-control study of 110 patients who bled during VKA therapy and 220 control patients free of bleeding under the same therapy. To achieve the same target INR, CT genotype and TT genotype control patients required less phenprocoumon (CC genotype 2.9 mg/d [95% confidence interval (CI): 2.6-3.2], CT genotype 2.6 mg/d [95% CI: 2.1-3.1], TT genotype 1.4 mg/d [95 % CI: 1.1-1.7]) or acenocoumarol (CC genotype 3.2 mg/d [95% CI: 2.9-3.5], CT genotype 2.3 mg/d [95% CI: 2.1-2.5], TT genotype 1.7 mg/d [95% CI: 1.3-2.1]) than CC genotype control patients. Compared with CC genotype individuals, carriers of at least one T allele had an increased risk of bleeding in the phenprocoumon users (crude odds ratio = 2.6, 95% CI: 1.2-5.7), but not in acenocoumarol users (crude odds ratio = 1.2, 95% CI: 0.6-2.3). CONCLUSION: These findings encourage taking further steps towards the evaluation of the use of VKORC1 genetic testing for bleeding prevention in individuals who receive VKA therapy.
No takes yet. Share an insight, caveat, or question.
Reitsma et al. (2005) conducted a case-control in Severe bleeding during vitamin K antagonist therapy (n=330). VKORC1 C1173T polymorphism (T allele carrier) vs. CC genotype was evaluated on Severe bleeding in phenprocoumon users (OR 2.6, 95% CI 1.2-5.7). Carriers of at least one T allele in the VKORC1 C1173T polymorphism had a increased risk of severe bleeding when using phenprocoumon compared to CC genotype individuals.
Synapse has enriched 10 related papers. Consider them for comparative context: